[1] C M PERRY S N. Didanosine: an updated review of its use in HIV infection.[J]. Drugs, 1999, 58 6: 1099-1135. DOI:
10.2165/00003495-199958060-00009[2] VIVEK ANANTHARAMAN Laura K M. Effects of Nucleoside Analogs on Native and Site-Directed Mutants of HTLV Type 1 Reverse Transcriptase[J]. Bioorganic Chemistry, 2000, 28 5: Pages 293-305. DOI:
10.1006/bioo.2000.1181[3] J J ERON. pol mutations conferring zidovudine and didanosine resistance with different effects in vitro yield multiply resistant human immunodeficiency virus type 1 isolates in vivo.[J]. Antimicrobial Agents and Chemotherapy, 1993, 37 7: 1480-1487. DOI:
10.1128/aac.37.7.1480[4] ERIC BENBRIK . Cellular and mitochondrial toxicity of zidovudine (AZT), didanosine (ddI) and zalcitabine (ddC) on cultured human muscle cells[J]. Journal of the Neurological Sciences, 1997, 149 1: Pages 19-25. DOI:
10.1016/s0022-510x(97)05376-8[5] H KANESHIMA. Human immunodeficiency virus infection of human lymph nodes in the SCID-hu mouse.[J]. Proceedings of the National Academy of Sciences of the United States of America, 1991, 88 10: 4523-4527. DOI:
10.1073/pnas.88.10.4523